Shire, SKP Solaraze deal

SkyePharma (LSE:SKP; SKYE) granted Shire (LSE:SHP; SHPGY) European marketing rights to its Solaraze diclofenac, a non-steroidal anti-inflammatory drug to treat actinic keratosis, for L12.9 million ($18.9 million). SKP is eligible for an additional L2.1 million payment related to launches in certain countries, and is eligible for royalties on sales. European rights to Solaraze previously were held by Bioglan (LSE:BGP), which is in receivership, and last year SKP notified BGP that it sought to terminate the deal (see BioCentury, Dec. 3, 2001). ...